Jim Chinitz, Chief Executive Officer.

During the past 20 years, Mr. Chinitz has become globally recognized for introducing new and leading edge technology to the research, pharmaceutical and diagnostic communities. Prior to co-founding Population Diagnostics, he held various positions on elite commercial teams within the pioneering life science companies, Hoffmann-La Roche, Applied Biosystems (nyse:ABI), Affymetrix (nasdaq:AFFX), Third Wave Technologies (nasdaq: TWTI) and Enzo Life Sciences (nyse:ENZ). Director and Executive Management level positions were amongst these roles. His industry expertise in sales, marketing and business development were essential in the new product launches of DNA sequencing, PCR, gene expression and genotyping technologies which have today, become the mainstream tools and methods for human disease research. In fact, these were the tools which were adopted for the Human Genome Project. His role in the worldwide market adoption of high density genome wide scanning technology (“microarrays”) has led Mr. Chinitz’s vision for the acceleration of genetic discoveries and their conversion into simple diagnostic tests used by physicians. Mr. Chinitz’s BS degree is in Biochemical Pharmacology from SUNY Buffalo’s School of Pharmacy and he currently serves on the board of the Cold Spring Harbor Laboratory DNA Learning Center.

Dr. Eli Hatchwell, Chief Scientific Officer and Co-Founder

 Dr. Hatchwell is an MD PhD from the United Kingdom. He qualified in Medicine from Cambridge University in 1985 and obtained his D Phil from Oxford University in 1995. He is a fully qualified Medical Geneticist and has spent many years in clinical practice. He has been engaged in full time research for 16 years and has been an Investigator at Cold Spring Harbor Laboratories and SUNY at Stony Brook. In addition to authoring many articles in peer reviewed journals, he is a regular reviewer for many journals as well as an editor of a series of books aimed at educating medical specialists in the field of genetics. The current focus of Dr. Hatchwell’s work is on the analysis of copy number variation in a range of human genetic disorders, including autism and congenital heart disease.  It is because of his experience in both the clinical and research arenas that Dr. Hatchwell’s insights are invaluable. He has a keen sense of what needs to be done experimentally and what gaps exist in our knowledge.  In particular, it is through his experience in copy number analysis that he has realized the dramatic and immediate need for a comprehensive understanding of normal variation, both as a tool for academic researchers but also as a vital piece of infrastructure for the commercial biotech and diagnostic industry. Dr. Hatchwell collaborates with leaders in the field of human genetics and microarray analysis and is well respected in terms of his knowledge and experience in both arenas.